J&J Faces Further Criticism Over Bedaquiline Despite Licensing Deal
Agreement With Stop TB Partnership Allows For Generic Versions Of Sirturo In LMICs
Johnson & Johnson has reached an agreement with the Stop TB Partnership that will allow generic bedaquiline versions of the firm’s Sirturo brand to be supplied in low-and middle-income countries where patents remain in effect – but critics say the deal does not go far enough.
